
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
Short Title: C6461016
Enrollment Status: Recruiting
NCT #: NCT07392892
Specialty Area: Oncology
Condition Studied: Advanced or Metastatic Gastroesophageal Cancer
Age Groups: Adult; Older Adult
Phase: II/III
Study Information
Summary / Purpose
The study is testing a new investigational medicine called PF-08634404, given through an IV, in combination with standard chemotherapy to see if this new combination can better treat advanced stomach cancer, cancer at the junction between the stomach and esophagus, or esophageal cancer that has either spread to other parts of the body or cannot be removed with surgery compared to current standard treatment options.
Who Can Participate
- Adults 18+ years of age
- Have previously untreated, locally advanced or metastatic gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma that is HER2-negative and PD-L1 positive
- Have ECOG performance status of 0–1
- No active or untreated brain metastases
- No significant recent bleeding or cardiovascular events
- No serious uncontrolled medical conditions such as interstitial lung disease or autoimmune disease requiring treatment, or other conditions that would make participation unsafe.
What's Involved
- Receiving PF-08634404 in combination with standard chemotherapy or a comparator treatment regimen administered in repeating cycles through intravenous (IV) infusions and/or orally.
- Attending regular clinic visits for safety monitoring, including physical exams, blood tests, and imaging scans to evaluate tumor response.
Principal Investigator

Additional Information
Address: 1500 E 2nd St. Reno, NV 89502
General Research: 775-982-3646
Oncology Research: 775-982-5050
Email: Renown-CRD@renown.org
Complete Study Details: https://clinicaltrials.gov/study/NCT07392892
Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.